Singapore, Nov. 14 -- Vaxcellbio, a South Korea-based immuno-oncology company, has entered into a strategic Memorandum of Understanding (MoU) with the Integrated Research Institute of Pharmaceutical Sciences at College of Pharmacy, Seoul National University (SNU) to co-develop a drug delivery system (DDS) formulation for antibody-based therapies targeting macular degeneration.

Under the agreement, the two parties will establish a broad collaborative framework that covers- Joint research on DDS platforms for antibody therapeutics; Shared use of equipment, technology, and market intelligence; Administrative and technical support for collaborative research projects.

Macular degeneration is one of the three leading causes of blindness world...